Literature DB >> 1643749

Immunological evaluation of late complement component-deficient individuals.

A E Platonov1, V B Beloborodov, D I Gabrilovitch, V V Khabarova, L V Serebrovskaya.   

Abstract

The possible contribution of additional immunologic variables to the susceptibility of late complement component-deficient individuals to meningococcal disease has not been systematically examined in previous studies. Thus, we studied three groups of patients: (1) 24 healthy individuals, (2) 8 complement-sufficient individuals with a history of recurrent bacterial meningitis, and (3) 19 complement-deficient individuals with prior meningococcal infection. No statistical differences were noted among the three groups for the following parameters: the absolute number and the percentage of lymphocytes; CD3+, CD4+, CD8+, CD20+, and CD16+ cells; and the CD4+/CD8+ ratio. The concentration of C4 and circulating immune complexes was also similar among the groups. The concentrations of IgG, IgM, and IgA were slightly, but significantly, decreased in the complement-deficient individuals. Of interest, the coefficient of spontaneous and lipopolysaccharide-stimulated activation of neutrophils was significantly depressed in the deficient individuals. We hypothesize that the terminal complement components may participate in maximal neutrophil activation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1643749     DOI: 10.1016/0090-1229(92)90186-r

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  4 in total

1.  How partial C7 deficiency with chronic and recurrent bacterial infections can mimic total C7 deficiency: temporary restoration of host C7 levels following plasma transfusion.

Authors:  R Würzner; A E Platonov; V B Beloborodov; A I Pereverzev; I V Vershinina; B A Fernie; M J Hobart; P J Lachmann; A Orren
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

2.  Meningococcal disease and polymorphism of FcgammaRIIa (CD32) in late complement component-deficient individuals.

Authors:  A E Platonov; E J Kuijper; I V Vershinina; G A Shipulin; N Westerdaal; C A Fijen; J G van de Winkel
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

3.  Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine.

Authors:  A E Platonov; V B Beloborodov; L I Pavlova; I V Vershinina; H Käyhty
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

Review 4.  Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.

Authors:  Dan M Granoff
Journal:  Vaccine       Date:  2009-05-23       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.